Clinical Trial Update: Daunorubicin Hydrochloride, Cytarabine and Oblimersen Sodium in Treating Patients With Previously Untreated Acute Myeloid Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating daunorubicin hydrochloride, cytarabine, and oblimersen sodium in previously untreated acute myeloid leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Acute Myeloid Leukemia Untreated
• Acute Myeloid Leukemia with
• Acute Myeloid Leukemia with 11q23 Abnormalities
• Acute Myeloid Leukemia with Inv

Drugs mentioned

• CYTARABINE (CYTARABINE)
• Daunorubicin hydrochloride (daunorubicin hydrochloride)
• Genasense (oblimersen sodium) (oblimersen sodium)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Phase 3 | Status: COMPLETED